St. Jude Medical Trifecta aortic valve: results from a prospective regional multicentre registry
Key result
The Trifecta aortic bioprosthesis provided favorable clinical and hemodynamic outcomes, demonstrating 87% freedom from all-cause mortality at 30 months and significant reductions in transvalvular gradients.
Why the study?
Does the Trifecta aortic bioprosthesis provide favorable clinical and hemodynamic outcomes in patients undergoing aortic valve replacement?
Population
178 consecutive patients undergoing aortic valve replacement, average age 75.4 ± 7.7 years, 53% men…
Design
Cohort
Follow-up
Median 20.5 months (range: 1-34)
Authors
Discussion
Loading...
Member takes
Implication
Supports favorable early Trifecta performance in aortic replacement; leaves open long-term durability versus alternatives.
Study Design
Type
Observational (n=178)
Multicenter
Yes
Structured PICO
Does the Trifecta aortic bioprosthesis provide favorable clinical and hemodynamic outcomes in patients undergoing aortic valve replacement?
P
Population
178 consecutive patients (mean age 75.4 years, 46.6% female) undergoing primary aortic valve replacement with the Trifecta bioprosthesis, followed for a median of 20.5 months.
I
Intervention
Aortic valve replacement with the St. Jude Medical Trifecta bioprosthesis (stented pericardial heart valve)
O
Outcome
Early clinical and hemodynamic performances at discharge, 6-months and at 1-year postoperativelyhard clinical
The Trifecta bioprosthesis demonstrated favorable early clinical outcomes and excellent hemodynamic performance in patients undergoing aortic valve replacement.
Limitations
- Relatively small sample size
- Lack of a control group for comparison with other bioprosthetic and stentless valves
- Heterogeneous patient population regarding surgical access and implant techniques
- Short follow-up time
Cite This Study
Mariscalco et al. (2015) conducted an observational in Aortic valve disease requiring replacement (n=178). St. Jude Medical Trifecta aortic bioprosthesis was evaluated on Freedom from all-cause mortality at 30 months. The Trifecta aortic bioprosthesis provided favorable clinical and hemodynamic outcomes, demonstrating 87% freedom from all-cause mortality at 30 months and significant reductions in transvalvular gradients.